Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design
/in Dendritic Cells, Glioblastoma, International PublicationsCancer stem cells: perspectives of new therapeutical approaches for breast cancer
/in Breast Cancer, Dendritic Cells, International PublicationsOncolytic viruses for the treatment of neuroendocrine tumors
/in International Publications, Newcastle Disease VirusImmunotherapy for the treatment of prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerCancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma
/in Dendritic Cells, International PublicationsRandomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerImportant role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusDendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study
/in Dendritic Cells, International Publications, Pancreatic CancerImmune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer